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BACKGROUND The Fragmin and fast Revascularization during InStability in Coronary artery disease (FRISC
II) trial compared the effectiveness of an early invasive versus a noninvasive strategy in terms
of the incidence of death and myocardial infarction (MI) in patients with unstable coronary
artery disease (CAD).
OBJECTIVES In this subanalysis, we sought to evaluate gender differences in the effect of these different
strategies.
METHODS The patients (749 women and 1,708 men) were randomized to early invasive or noninvasive
strategies. Coronary angiography was performed within the first 7 days in 96% and 10% of the
invasive and noninvasive groups, respectively, and revascularization was performed within the
first 10 days in 71% and 9% of the invasive and noninvasive groups, respectively.
RESULTS Women presenting with unstable CAD were older, but fewer had previous infarctions, left
ventricular dysfunction and elevated troponin T levels. Women had fewer angiographic
changes. There was no difference in MI or death at 12 months among women in the invasive
and noninvasive groups (12.4% vs. 10.5%, respectively), in contrast to the favorable effect in
the invasively treated group of men (9.6% vs. 15.8%, p , 0.001). In an interaction analysis,
there was a different effect of the early invasive strategy for the two genders (p 5 0.008).
CONCLUSIONS Women with symptoms and/or signs of unstable CAD are older, but still have less severe
CAD and a better prognosis compared with men. In contrast to its beneficial effect in men,
an early invasive strategy did not reduce the risk of future events among women. Further
research is warranted to identify the most appropriate treatment strategy in women with
unstable CAD. (J Am Coll Cardiol 2001;38:41–8) © 2001 by the American College of
Cardiology
The attitudes, treatment methods and rehabilitation goals of
doctors differ with respect to men and women, and in recent
years, several centers have reported gender differences in the
diagnosis and medical treatment of cardiovascular disease,
to the detriment of women (1–4). In part, the less aggressive
treatment of women’s disease can be explained by the results
from early studies (5–9) of coronary artery bypass graft
surgery (CABG), which showed a markedly increased risk
of death among women. Later studies of CABG have
shown a higher preoperative mortality among women (10),
although the long-term results have been comparatively
similar between the genders (8). Female gender is also a
known risk factor for mortality and morbidity in relation to
a percutaneous coronary intervention (PCI) (11–13). This
has been partly explained by women’s older age, cardiac
failure, severe vascular disease, smaller coronary arteries, and
so forth. The long-term results of PCI during this period,
however, have been equal to those displayed by men
(13–18). In the Fragmin and fast Revascularization during
InStability in Coronary artery disease (FRISC II) invasive
trial, an early invasive strategy was compared with a nonin-
vasive strategy in patients with unstable coronary artery
disease (CAD) treated with optimal antithrombotic medi-
cation. The trial showed the superiority of the invasive
strategy over the more conservative approach. However, in
predefined subgroups, there was a significant interaction
between female gender and the invasive strategy (14).
The aim of the present analysis of the FRISC II is to
compare men and women with unstable CAD in terms of their
clinical variables at hospital admission, coronary anatomy,
events during follow-up and outcome of the randomized
invasive strategy compared with the noninvasive strategy.
METHODS
The FRISC II study was a prospective, randomized, mul-
ticenter trial with parallel groups. The invasive versus
noninvasive comparison was carried out in a factorial design.
Half of the patients within each group were randomized to
receive continued treatment with subcutaneous dalteparin or
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placebo for three months. All patients received open-label
dalteparin treatment for at least five days and always until
the invasive procedure. The comparison of the invasive
versus noninvasive strategies was open. Patients meeting the
entry criteria were randomized, and stratified by center, to
one of four treatment regimens as soon as possible after
hospital admission, but at the latest within 72 h after the
start of open-label dalteparin (or standard heparin) admin-
istration. The treatment groups included: 1) the invasive
strategy and extended treatment with dalteparin; 2) the
invasive strategy and long-term placebo; 3) the noninvasive
strategy and extended treatment with dalteparin; and 4) the
noninvasive strategy and long-term placebo. In the invasive
strategy, the target was to perform all invasive procedures
within seven days after starting open-label dalteparin.
Patients. Patients were eligible for inclusion if they had
symptoms of ischemia that were increasing or occurring at
rest or if they had symptoms warranting suspicion of acute
myocardial infarction (MI), with the last episode preceding
the first dose of dalteparin or standard heparin by ,48 h.
Furthermore, myocardial ischemia had to be verified by
electrocardiography (ST segment depression $0.1 mV or
T-wave inversion $0.1 mV) or by elevation of biochemical
markers: creatine kinase-MB isoenzyme (CK-MB) .6 mg/l,
troponin T .0.10 mg/l, qualitative test for troponin T as
positive or catalytic activity of CK, CK-B or CK-MB above
the local decision limit for the diagnosis of MI. The details
of exclusion criteria, the follow-up procedure and concom-
itant therapies are described in previous reports (15,16).
The study complied with the Declaration of Helsinki,
and all local ethics committees approved the protocol.
Written, informed consent was received from all patients.
Interventional strategies. The invasive strategy required
coronary angiography within a few days of enrollment,
aiming for revascularization within seven days of starting
open-label dalteparin (or standard heparin). Revasculariza-
tion was recommended for all patients with $70% diameter
obstruction in any artery supplying a significant proportion
of the myocardium. If there were one or two target lesions,
PCI was recommended, whereas CABG was preferred in
patients with three-vessel or left main coronary artery
(LMCA) disease.
The noninvasive strategy included coronary angiography
in patients with refractory or recurrent symptoms, despite
maximal medical treatment or severe ischemia on a predis-
charge symptom-limited exercise test (15). During long-
term follow-up, invasive procedures were considered, re-
gardless of randomized strategy, for all patients with
incapacitating symptoms, recurrence of instability or MI.
In accordance with these guidelines, coronary angiogra-
phy was performed within the first 7 days in 96% of the
invasive group and in 10% of the noninvasive group, and
revascularization was performed within the first 10 days in
71% and 9% of the invasive and noninvasive groups,
respectively.
Statistical analysis. Statistical analysis was performed on
an intention-to-treat basis. Comparison of continuous vari-
ables was performed using the unpaired t test. The Mantel-
Haenszel chi-square test was used to test the significance
between the two strategy groups. Efficacy analyses were
based on point estimates of events occurring from the start
of open-label dalteparin treatment until 12 months and
included only patients with an adjudicated event or with
recorded absence of the evaluated event until at least day
335 of follow-up. The probability curves were constructed
using the Kaplan-Meier method. Multivariate logistic re-
gression analysis was performed to evaluate the effect of
gender as an independent prognostic factor relating to the
predefined combined end points of MI and death. In our
model, we adjusted for the following clinical variables: age,
diabetes, medically treated hypertension, smoking, history
of angina pectoris for at least three months, previous MI,
ST segment depression at hospital admission, troponin T
$0.10 mg/l at admission and randomized long-term (three
months) treatment with either low-molecular weight hep-
arin (dalteparin) or placebo. When the model was used on
the entire data (i.e., both strategy groups), then the ran-
domized strategy (invasive or noninvasive) and the interac-
tion variable of gender-strategy were included in the statis-
tical model. In the invasive strategy group, a second
multivariate analysis was performed when the presence or
absence of angiographically significant stenosis was adjusted
for. In all tests, p , 0.05 was considered statistically
significant. The coordinating investigators performed data
processing and statistical analyses using the SPSS version
10.0.5 statistical program for personal computers (SPSS,
Inc., Chicago, Illinois).
RESULTS
Baseline characteristics and gender. There were 749
women and 1,708 men in the study. The distribution of all
patients in relation to strategy, gender and revascularization
is presented in Figure 1. The women were older than the
men, and there were also some gender differences in the risk
factors and in the medications at admission (Table 1). More
women had previous angina treated with anti-anginal med-
ication, and more men had previous MI and pathologic Q-
waves at admission. Fewer women had left ventricular
dysfunction and elevated troponin T levels. At admission,
there was no difference in the rate of ST segment depression
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
CK-MB 5 creatine kinase-MB isoenzyme
FRISC 5 Fragmin and fast Revascularization during
InStability in Coronary artery disease study
LMCA 5 left main coronary artery
MI 5 myocardial infarction
PCI 5 percutaneous coronary intervention
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between women and men; however, T-wave inversion was
seen more often in women. There were only minor differ-
ences in baseline characteristics between the two strategy
groups within the genders. Women in the invasive strategy
group had more Canadian Cardiovascular Society (CCS)
class III/IV angina (35%), compared with women in the
noninvasive group (26%) (p 5 0.008). There were no other
gender-related differences in the baseline variables between
the invasive and noninvasive groups.
There were more patients without significant coronary
stenosis (p , 0.001) among the women. Men had more
severe and extended coronary disease: LMCA disease and
three- or two-vessel disease with proximal left anterior
descending coronary artery stenosis was more prevalent in
men (p 5 0.001) (Table 2).
There were several specific differences in the clinical
profile of patients recommended for CABG (Table 3).
Female patients who underwent CABG in the invasive
group had more previous MI and diabetes mellitus com-
pared with women in the PCI and noninvasive groups; this
was not the case with men (Table 3).
Noninvasive group: gender differences in outcome. In
the noninvasive group, coronary angiography was performed
in 52% of both women and men during the first 12 months
(p 5 NS). There was no difference between the genders in
terms of the overall frequency of the intervention or in
selection of the type of intervention. In the noninvasive
strategy group, the incidence of MI and of the combined
end point of death or MI was significantly less in women
than in men during 12 months of follow-up (Table 4). In
Figure 1. The number of patients in relation to randomized strategy, gender and first intervention. CABG 5 coronary artery bypass graft surgery; PCI 5
percutaneous coronary intervention.
Table 1. Baseline Characteristics
Variable
Women
(n 5 749)
Men
(n 5 1,708)
Total
(n 5 2,457)
p
Value
Age (mean 6 SD, yrs) 68 6 8 64 6 10 65 6 9 ,0.001
Coronary risk factors (%)
Hypertension 36 28 30 ,0.001
Cholesterol
.5.5 mmol/l
68 53 58 ,0.001
Current smoker 29 31 30 NS
Diabetes mellitus 11 13 12 NS
Previous and current
cardiac disease (%)
Previous MI 18 24 22 0.001
Angina history .48 h 72 67 68 0.015
CCS angina class III/IV 31 30 30 NS
Chest pain at rest 83 80 81 NS
Troponin T $0.1 mg/l 47 62 58 ,0.001
LVEF ,45% 9 14 13 0.002
Medication at admission (%)
Acetylsalicylic acid 35 36 35 NS
Beta-blocker 37 30 32 0.001
ACE inhibitor 13 12 12 NS
Calcium antagonist 19 17 18 NS
Long-acting nitrate 25 11 15 ,0.001
Diuretic 22 18 19 0.017
Statin 10 10 10 NS
ECG at admission (%)
ST segment depression
at entry
49 45 46 NS
T-wave inversion 72 64 66 ,0.001
Pathologic Q-waves 14 20 18 0.001
ACE 5 angiotensin-converting enzyme; CCS 5 Canadian Cardiovascular Society;
ECG 5 electrocardiogram; LVEF 5 left ventricular ejection fraction; MI 5
myocardial infarction; NS 5 not significant.
Table 2. Gender Distribution in Severity of Coronary Artery
Disease in Patients Randomized to the Invasive Strategy
Women Men
None 85 (24.6%) 81 (9.5%)
One-vessel disease 110 (31.9%) 239 (28.0%)
Two-vessel disease 54 (15.7%) 240 (28.1%)
Three-vessel disease 72 (20.9%) 225 (26.3%)
LMCA disease 24 (7.0%) 70 (8.2%)
LMCA/three-vessel disease/
two-vessel disease with
proximal LAD stenosis
111 (32.2%) 368 (43.0%)
LAD 5 left anterior descending coronary artery; LMCA 5 left main coronary artery.
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the multivariate analysis of the noninvasive group (Table 5),
male gender was found to be an independent risk factor for
death or MI at 12 months.
Invasive group: gender differences in outcome. In the
invasive strategy group, 98% of men and 99% of women
underwent coronary angiography. The median time from
admission to coronary angiography was four days. The
results of these coronary angiograms are presented in Table
2. There were fewer interventions in the female group (n 5
234 [67%]) than in the male group (n 5 721 [82%], p ,
0.001), but among those who were revascularized, there
were no significant differences in the choice of procedure
The outcomes are shown in Table 6. There was a trend
toward a more severe outcome in the female group, but the
difference was not statistically significant.
In the multivariate analysis (Table 5), gender was not
found to be an independent risk factor when adjusting for
the same clinical and baseline variables as in the noninvasive
group. However, if the presence or absence of significant
stenosis after angiography was also included in the statistical
model, female gender was found to be an independent risk
factor for death or MI.
Outcomes of different types of coronary intervention in
relation to gender (invasive group). Percutaneous coro-
nary intervention was the first and, in most cases, the only
intervention in 530 patients (43%; 133 women and 397
men) during follow-up. The corresponding number of
patients who had CABG was 425 (35%; 101 women and
324 men). In 267 patients (22%; 114 women and 153 men),
no intervention was performed.
There was no difference in outcome between the two
genders if the first procedure was a PCI or if no intervention
was performed. After CABG, there was a significantly
worse outcome at 12 months in women compared with men
(Table 7).
All patients: outcomes and interaction. Four patients, at
their request, were lost to follow-up. The total mortality rate
Table 3. Some Background and Clinical Variables of the Different Strategy Groups
Women
CABG
p
Value
PCI
p
Value
Invasive
(n 5 101)
Noninvasive
(n 5 80)
Invasive
(n 5 133)
Noninvasive
(n 5 77)
Age (yrs) 70 68 NS 66 65 NS
Days to angiography 4 30 ,0.001 4 42 ,0.001
Days to revascularization 8 50 ,0.001 5 52 ,0.001
Diabetes (%) 26 13 0.027 6 9 NS
Previous MI (%) 37 14 0.001 11 13 NS
Smoker (%) 21 38 0.013 37 33 NS
Three-vessel disease/LMCA disease (%) 78 76 NS 8 8 NS
Men
CABG PCI
Invasive
(n 5 324)
Noninvasive
(n 5 185)
p
Value
Invasive
(n 5 397)
Noninvasive
(n 5 183)
p
Value
Age (yrs) 67 65 NS 62 61 NS
Days to angiography 4 41 ,0.001 4 40 ,0.001
Days to revascularization 9 58 ,0.001 4 50 ,0.001
Diabetes (%) 12 16 NS 14 10 NS
Previous MI (%) 34 36 NS 18 18 NS
Smoker (%) 25 23 NS 35 39 NS
Three-vessel disease/LMCA disease (%) 77 75 NS 9 16 0.021
CABG 5 coronary artery by pass graft surgery; LMCA 5 left main coronary artery; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention.
Table 4. First Revascularization Procedure and Outcome at
12 Months of Follow-Up in the Group Randomized to the
Noninvasive Strategy According to Gender
Women
(n 5 401)
Men
(n 5 834)
p
Value
Intervention 157 (39%) 368 (44%) NS
PCI 77 (19%) 183 (22%) NS
CABG 80 (20%) 185 (22%) NS
Death 13 (3.2%) 35 (4.2%) NS
MI 34 (8.5%) 109 (13.1%) 0.019
Death/MI 42 (10.5%) 132 (15.8%) 0.005
Abbreviations as in Table 3.
Table 5. Effect of Female Gender on Death or Myocardial
Infarction at 12 Months
Group Tested* OR 95% CI p Value
Noninvasive strategy group 0.64 0.43–0.97 0.034
Invasive strategy group 1.46 0.96–2.23 NS
Invasive strategy group, also adjusted
for presence of coronary stenosis
1.72 1.11–2.65 0.014
All patients, also adjusted for strategy
(invasive/noninvasive)
0.91 0.68–1.22 NS
*Multivariate analysis using a logistic regression model adjusting for age, diabetes,
hypertensive medical treatment, smoking, history of angina pectoris (.3 months),
previous myocardial infarction, ST segment depression at admission, troponin T .0.1
mg/liter and randomized long-term (3 months) dalteparin/placebo treatment.
CI 5 confidence interval; OR 5 odds ratio.
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at 12 months of follow-up was 3.1% (3.6% for women and
2.8% for men, p 5 NS). The procedure-related mortality
rate was, according to the End Points Committee, 0.3% in
men and 1.8% in women (p 5 0.002).
The event rates for women and men according to strategy
group are presented in Figure 2A and B.
In the multivariate analysis of all patients, adjustment for
the randomized strategy and for the same variables as in the
noninvasive strategy group was made. Gender was not
found to be an independent risk factor for death or MI
(Table 5). An interaction analysis was performed with
introduction of the interaction variable of gender-strategy.
In the model, this interaction variable was significant (p 5
0.008), indicating a different response to the early invasive
strategy in men and women.
DISCUSSION
In the FRISC II study, we found that women and men
differed with respect to several clinical characteristics. The
women were older and had more hypertension, hypercho-
lesterolemia and a higher rate of previous angina, but fewer
of them experienced a previous or index MI compared with
men. Women had a higher frequency of angiographically
normal coronary arteries and, among those with significant
coronary lesions, a lower rate of two- or three-vessel disease
compared with men, which is a common phenomenon in
mixed-gender study groups of patients with ischemic heart
disease (17–23). It could be expected that this difference
should have been less in this group of patients, where all of
the women were older and postmenopausal and all patients
had ischemic electrocardiographic changes or raised bio-
chemical markers of MI, or both. However, T-wave inver-
sion, without elevation of biochemical markers, was more
commonly seen in the female group. This is known to be
less specific for CAD than ST segment changes or elevation
of biochemical markers (24). Therefore, despite the same
inclusion criteria, the female cohort represented a lower risk
group with no or single-vessel disease in the majority of
cases (56%); hence, they had little to gain from invasive
procedures with the inherent risks of side effects.
Noninvasive strategy arm. Fewer interventions were made
in women, because more women had normal coronary
arteries or single-vessel disease. It is well known that
patients without significant stenosis or single-vessel disease
have a lower event rate compared with patients with
significant two- or three-vessel disease or LMCA stenosis.
In the present study, patients with no coronary stenosis had
an excellent prognosis, with no deaths occurring during the
12-month follow-up period. Thus, the lower event rate seen
in the noninvasive female group versus the noninvasive male
group could be explained, to a large extent, by a greater
proportion of patients with normal coronary angiograms
among women. To illustrate this, the following calculation
was performed. The rate of normal coronary angiograms
and the prognosis in this group of patients were supposed to
be the same in the noninvasive as in the invasive strategy
group both for men and women. The presumed number of
patients without coronary stenosis was excluded from the
calculation. In the rest of the noninvasive group, the rate of
death or MI within 12 months was calculated to 13.2% in
women and 16.4% in men (p 5 0.186, risk ratio 0.80, 95%
confidence interval 0.58 to 1.11). Thus, after this calculated
compensation for the lower prevalence of significant CAD
among women, there was no actual gender difference in
prognosis in the noninvasive strategy arm.
Table 6. Outcomes at 12 Months in the Group Randomized to
the Early Invasive Strategy With Respect to Gender
Women
(n 5 348)
Men
(n 5 874)
p
Value
Death 14 (4.0%) 13 (1.5%) NS
MI 32 (9.2%) 73 (8.4%) NS
Death/MI 43 (12.4%) 84 (9.6%) NS
MI 5 myocardial infarction.
Table 7. Outcomes at 12 Months of Follow-Up in Women and Men Randomized to the Early
Invasive Strategy in Relation to the Type of First Coronary Intervention
Event
Women/Men
n
Women
n (%)
Men
n (%)
p
Value
RR
(95% CI)
Death
Intervention
CABG 101/324 10 (9.9%) 4 (1.2%) ,0.001 8.79 (2.69–28.7)
PCI 133/397 2 (1.5%) 4 (1.0%) NS 1.50 (0.27–8.28)
No intervention 114/153 2 (1.8%) 5 (3.3%) NS 0.53 (0.10–2.80)
MI
Intervention
CABG 100/322 12 (12.0%) 16 (5.0%) ,0.014 2.61 (1.19–5.72)
PCI 133/397 18 (13.5%) 54 (13.6%) NS 0.99 (0.56–1.77)
No intervention 114/153 2 (1.8%) 3 (2.0%) NS 0.89 (0.15–5.43)
Death/MI
Intervention
CABG 100/322 19 (19.0%) 19 (5.9%) ,0.001 3.74 (1.89–7.40)
PCI 133/397 20 (15.0%) 58 (14.6%) NS 1.03 (0.60–1.80)
No intervention 114/153 4 (3.5%) 7 (4.6%) NS 0.76 (0.22–2.66)
CI 5 confidence interval; RR 5 risk ratio; other abbreviations as in Table 3.
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Invasive strategy arm. In the invasive group, there was no
gender difference. One reason for this finding could be the
higher procedure-related mortality in association with
CABG among women. These findings are in accordance
with the earlier randomized studies in which CABG-related
mortality was higher among women (9,21). This is also in
accordance with the Thrombolysis In Myocardial Infarction
(TIMI IIIB) substudy in which the 42-day mortality rate
tended to be higher in operated-on women (8.5%) than in
operated-on men (2.2%) (p 5 0.05) (18). However, subse-
quent larger scale studies have, to some degree, rejected
these findings and have shown that the gender difference
can be explained, to a large extent, by differences in
comorbidities and other confounding factors (10,25). This
explanation might also be the main reason for the outcome
of CABG in the present trial, where women who underwent
CABG were older and more often diabetic than men.
Thus, it is possible to speculate that the higher
procedure-related mortality in women was due to the fact
that CABG-treated women formed an especially high-risk
group at surgery because of age, diabetes and more frequent
previous MIs. It should also be observed that mortality in
the CABG-treated men in the invasive arm was surprisingly
low and not different from that in the PCI-treated cohort,
Figure 2. Cumulative probability of death or myocardial infarction during 12-month follow-up in (A) women and (B) men in relation to randomized
strategy (solid line 5 noninvasive strategy; dotted line 5 early invasive strategy). ns 5 not significant.
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despite considerable differences in risk factors between these
groups. Thus, it cannot be excluded that the gender differ-
ence in CABG-related mortality in the invasive group was,
to a large extent, a play of chance and that the overall
mortality among the CABG-treated patients was the most
representative procedure-related risk, regardless of gender.
Multivariate analysis. In the multivariate analysis, there
was a clear gender-strategy interaction, even when taking
into consideration confounding factors. The interaction
analysis showed a different effect of the early invasive
strategy for the two genders. Thus, in the present trial,
women did not benefit from an early invasive strategy when
they had unstable CAD, in contrast to men. This is partly
attributable to a higher CABG-related mortality in women.
However, subgroup analysis of the effect of the different
types of intervention was not predefined in the FRISC II
study. Furthermore, selection of the invasive procedure
(PCI vs. CABG) was based on a “clinical decision” and not
on randomization. This could have resulted in a concentra-
tion of high risk factors in women chosen for surgery.
Consequently, it is important to be very cautious with the
interpretation of these findings. The final evaluation of the
efficacy of an early invasive strategy in women with unstable
CAD will have to await the long-term follow-up of the
present trial and the outcome of other ongoing trials on the
same subject.
Study limitations. This study is based on a predefined
substudy of the FRISC II invasive trial, analyzing gender
differences. The numbers are too small and not powered
enough to draw final conclusions, but they can be used to
generate a hypothesis. As in the main study, all eligible
patients were not included due to exclusion criteria, which is
a limitation of all clinical trials. For definite knowledge, it is
necessary to conduct a trial with enough power to detect
differences in the early invasive treatment of women with
unstable CAD.
Conclusions. We found that women in the FRISC II
study had less advantage of an early invasive strategy,
compared with men. The results emphasize that women
with symptoms and/or signs of unstable CAD have less
advanced atherosclerosis and a better prognosis, but often
have important comorbidities associated with an increased
invasive procedure-related risk. Therefore, despite demon-
strating similar symptoms and signs of unstable CAD,
women have less to gain from an early invasive strategy, at
least in the short term. Thus, further research is warranted
to identify women who are likely to benefit from or be
harmed by an early invasive approach.
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